Journal article
Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk
Abstract
BACKGROUND: In the CANVAS (Canagliflozin Cardiovascular Assessment Study) program, canagliflozin reduced the risk of heart failure (HF) hospitalization among individuals with type 2 diabetes mellitus (T2DM).
OBJECTIVES: The purpose of this study was to evaluate heterogeneity in absolute and relative treatment effects of canagliflozin on HF hospitalization according to baseline HF risk as assessed by diabetes-specific HF risk scores (WATCH-DM …
Authors
Khan MS; Segar MW; Usman MS; Patel KV; Van Spall HGC; DeVore AD; Vaduganathan M; Lam CSP; Zannad F; Verma S
Journal
JACC Heart Failure, Vol. 11, No. 7, pp. 825–835
Publisher
Elsevier
Publication Date
July 2023
DOI
10.1016/j.jchf.2023.03.025
ISSN
2213-1779